Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Drug Nomenclature01:17

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between anticholinergic activity and xerostomia and/ or xerophthalmia in the elderly: systematic review.

BMC pharmacology & toxicology·2022
Same author

[Failure mode effect analysis applied to preparation of intravenous cytostatics].

Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial·2015
Same author

Assessment of new drugs in a tertiary hospital using a standardized tool.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2013
Same author

[Health care models for patients with multiple chronic conditions and the role of the hospital pharmacy/the hospital pharmacist].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2013
Same author

[Indirect comparisons, author response].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2013
Same author

[Comment to the article: « Program of pharmacy care in patients with chronic diseases »].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2013

Related Experiment Video

Updated: Jun 3, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Consensus method to update the GINF formulary request form.

R Marín-Gil1, B Santos-Ramos, S Flores-Moreno

  • 1Pharmacy Department, Virgen del Rocío University Hospital, Seville, Spain. romagil79@hotmail.com

Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|March 29, 2011
PubMed
Summary

A revised Guideline for the Introduction of New Drugs in the Formulary (GINF) form was developed using expert consensus and evidence. This updated GINF form incorporates user feedback and international best practices for drug formulary decisions.

More Related Videos

Primary Dissociated Midbrain Dopamine Cell Cultures from Rodent Neonates
14:13

Primary Dissociated Midbrain Dopamine Cell Cultures from Rodent Neonates

Published on: November 5, 2008

Related Experiment Videos

Last Updated: Jun 3, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Primary Dissociated Midbrain Dopamine Cell Cultures from Rodent Neonates
14:13

Primary Dissociated Midbrain Dopamine Cell Cultures from Rodent Neonates

Published on: November 5, 2008

Area of Science:

  • Health Services Research
  • Pharmaceutical Policy

Background:

  • The Guideline for the Introduction of New Drugs in the Formulary (GINF) form requires updates to reflect current evidence and user needs.
  • Existing formulary request forms may not adequately capture essential information for drug evaluation.

Purpose of the Study:

  • To update the GINF form using the RAND/UCLA appropriateness method.
  • To enhance the GINF form by integrating user feedback, scientific literature, and expert judgment.

Main Methods:

  • A telephone survey with GINF form users and a literature review identified areas for improvement.
  • An expert panel assessed scenarios derived from user feedback and literature.
  • A consensus methodology, the RAND/UCLA appropriateness method, was employed.

Main Results:

  • 52 improvement proposals were generated, focusing on form structure (31) and process (21).
  • Six formulary request forms were reviewed from the scientific literature.
  • The final GINF form version includes 24 assessed scenarios addressing clinical trial validity, qualitative assessment, and local drug implications.

Conclusions:

  • A new, improved version of the GINF form has been successfully developed.
  • The update integrates user opinions, scientific evidence, and international experiences.
  • The RAND/UCLA appropriateness method ensured a rigorous, consensus-driven development process.